ArticleScience (New York, N.Y.)2018

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.

Agostinho G Rocha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.